YOLFTbeta
00

DongKoo Bio & Pharma Co. Ltd.

006620 · KQ · Healthcare / Pharmaceuticals

3,385.00KRW-15.00 (-0.44%)

Price History

Full chart

Market Stats

Previous Close3,400.00
Open3,430.00
Day Range3,210.00 – 3,430.00
52-Week Range3,315.00 – 6,161.03
Volume91.00K
Market Cap95.59B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield2.18%
Beta1.10
50-Day Avg3,662.20
200-Day Avg4,595.20

About

DongKoo Bio&Pharma. Co., Ltd. researches, develops, manufactures, and sells medicines in South Korea. The company offers prescribed medicines, such as liver disease, skeletal muscle relaxant, endocrine system, brain nervous system, urogenital, antiobestic, digestive system, circulatory organ, allergenic, mental disease, oral dermatology, external preparation of dermatology, antiseptic, antiviral, antifungal, antihistamines, antifebrile and anti-inflammatory analgesic, respiratory system, digestant, antiplatelet, other analgesics and antipyretics, nootropics and neurotonics, nonsteroidal anti-inflammatory, and oral hypoglycemic medicines; and antiphlogisnc enzyme, ophthalmic, dermatology external, and decongestants and nasal preparations, as well as non-selective a, ß-blockers and H+ pump inhibitors. It also provides cosmetic products under the CELL BLOOM brand; and SmartX, a kit-type SVF separation medical device for use in cosmetic surgery/anti-aging clinics and medical/treatments. The company was founded in 1970 and is headquartered in Seoul, South Korea.

Company Details

  • SectorHealthcare
  • IndustryPharmaceuticals
  • CEOMr. Cho Yong-Joon
  • Employees331
  • HeadquartersM State Building, Seoul, South Korea, 05836, Korea
  • Websitehttp://www.dongkoo.com

Leadership

  • Mr. Cho Yong-JoonPres

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue80.37B87.36B101.12B104.84B125.24B139.22B155.15B194.99B215.69B249.27B242.69B
Growth (%)-+8.70%+15.75%+3.67%+19.46%+11.16%+11.45%+25.68%+10.62%+15.57%-2.64%
Cost of Revenue30.88B34.84B40.25B43.45B54.55B58.60B62.71B77.01B83.49B97.25B98.19B
Gross Profit49.49B52.53B60.88B61.39B70.69B80.62B92.44B117.98B132.19B152.03B144.50B
Gross Margin61.58%60.12%60.20%58.56%56.44%57.91%59.58%60.50%61.29%60.99%59.54%
Operating Expense41.68B42.22B47.55B55.57B64.23B73.00B84.30B100.94B117.58B139.66B135.25B
Operating Income7.81B10.30B13.33B5.82B6.46B7.62B8.14B17.04B14.61B12.37B9.25B
Operating Margin9.72%11.79%13.18%5.55%5.16%5.47%5.25%8.74%6.77%4.96%3.81%
EBITDA-------14.59B22.53B13.99B73.84B
EBITDA Margin-------7.48%10.45%5.61%30.43%
Net Income4.03B10.91B10.94B4.57B15.10B9.14B9.33B6.61B11.81B2.04B50.27B
Net Income Margin5.01%12.49%10.82%4.36%12.06%6.57%6.01%3.39%5.48%0.82%20.71%
R&D2.82B2.11B3.68B-8.37B10.75B10.11B8.26B10.75B8.38B10.79B
R&D as % of Total Revenue3.51%2.42%3.64%-6.69%7.72%6.52%4.24%4.98%3.36%4.45%
Interest Expense0000430.43M430.83M415.63M1.04B1.76B2.89B3.51B
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.34%0.31%0.27%0.53%0.82%1.16%1.45%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets60.77B65.31B75.59B104.28B132.73B144.35B154.79B172.06B191.10B244.06B336.35B
Total Liabilities58.22B43.27B37.85B32.18B47.07B49.70B54.66B69.95B80.66B138.73B184.19B
Total Equity2.55B22.05B37.74B72.10B85.65B94.65B100.12B102.11B110.40B105.33B151.70B
Cash337.23M4.89B9.89B4.73B10.34B4.88B19.56B12.51B15.71B25.37B21.56B
Total Debt22.24B19.48B14.46B11.98B20.38B23.22B-----
Net Debt-----18.12B3.51B20.49B26.23B59.97B106.45B

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow6.93B12.59B9.51B-791.20M10.14B7.49B17.90B16.82B3.59B17.34B-4.29B
Investing Cash Flow-1.14B-885.57M-1.77B-32.21B-11.23B-12.56B463.93M-27.01B-5.13B-45.03B-
Financing Cash Flow-7.43B-7.11B-2.75B27.82B6.72B-361.45M-3.69B3.19B4.75B37.19B-
Capital Expenditure2.32B6.55B810.51M6.16B8.77B5.27B4.27B11.08B15.97B25.46B20.45B
Free Cash Flow-----2.53B2.03B12.43B5.74B-12.38B-8.12B-24.74B
Dividends Paid-942.92M942.92M--942.92M942.94M2.80B3.04B3.31B3.25B
FCF to OCF-----24.95%27.08%69.42%34.15%-345.29%-46.82%577.05%
Dividend Paid to FCF-----46.49%7.59%48.81%-24.54%-40.79%-13.12%

Earnings

Report DateMay 15, 2018Aug 14, 2018Nov 14, 2018Mar 12, 2019May 15, 2019Aug 14, 2019Nov 14, 2019Mar 9, 2020May 15, 2020Aug 13, 2020Nov 15, 2020Mar 9, 2021May 17, 2021Aug 17, 2021Nov 15, 2021Mar 21, 2022May 16, 2022Aug 16, 2022Nov 14, 2022Mar 13, 2023May 19, 2023Aug 11, 2023Nov 14, 2023Mar 20, 2024May 16, 2024Aug 14, 2024Nov 12, 2024Mar 18, 2025May 15, 2025Aug 12, 2025Nov 12, 2025Mar 16, 2026May 13, 2026Jun 30, 2026
EPS Estimate----------------------------------
EPS Actual100.7166.0096.0014.3378.005.5627.08421.5951.07193.0079.33-0.0125.00172.0083.0066.4481.0041.00123.003.0369.24129.6245.10183.67159.3783.31131.36-304.28-25.18397.64-59.721526.27-21.35-224.40
Surprise----------------------------------
TimingPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market-After-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-market-

Key Statistics & Ratios

Market Cap95.59B
Enterprise Value166.81B
Trailing P/E0.00
Forward P/E0.00
Price / Sales0.40
Price / Book0.67
Revenue (TTM)187.11B
Gross Profit (TTM)92.33B
EBITDA22.55B
Profit Margin4.49%
Operating Margin9.13%
Return on Equity-286.27%
Return on Assets6.61%
Shares Outstanding9.60M
Shares Float15.58M
Beta1.10
Dividend Yield2.18%
Dividend Rate0.00
Payout Ratio9.83%

Dividends

20251×
120.00Dec 29, 2025
20241×
120.00Dec 27, 2024
20231×
120.00Dec 27, 2023
20221×
110.00Dec 28, 2022
20211×
100.00Dec 29, 2021
20201×
33.33Dec 29, 2020
20191×
33.33Dec 27, 2019

Stock Splits

  • Mar 2, 2021959692:319897